What Major Medical Institutions Are NOT Saying About HBOT

You can learn a lot from what major medical institutions say about a treatment. But you can sometimes learn more from what they refuse to say.

This page documents the institutional silence around off-label HBOT — the cases where you'd expect a top-tier medical center to weigh in publicly and they have chosen, in some cases for decades, not to. Silence is not the same as endorsement of the opposite view. But when the same institutions that publish detailed patient guidance on dozens of other therapies have nothing on the public record for a $40,000 cash-pay protocol marketed to their patient population, that is worth paying attention to.

This is not an argument that off-label HBOT is bunk. It's an argument that you should know what the institutions you trust have and haven't actually said.

What this list is and isn't

To be precise about what this catalogs:

• Institutional silence — a major medical center has no published patient-facing guidance, policy statement, or position paper on a specific off-label HBOT use as of mid-2026, despite that use being heavily marketed to its patient population.
• Institutional skepticism — an institution has published something noncommittal or cautious, or has actively declined to offer the service, while peers and competitors offer it.
• Insurance non-coverage — Medicare, the VA, or private insurers have published policy explicitly declining to cover an HBOT indication.

What this list is not:

• A claim that any specific off-label use doesn't work
• A claim that any institution mentioned is "right" or "wrong" to be silent
• Medical advice — for any individual situation, talk to your physician

Institutions stay silent for many reasons. Legal risk, lack of internal expertise, ongoing internal review, deference to specialist societies, simple resource constraints. Silence doesn't equal skepticism in every case. But when the silence is uniform across multiple peer institutions for years on a heavily-marketed off-label use — that's a pattern worth noting.

HBOT for autism

What's being marketed

Hyperbaric oxygen therapy is widely promoted to families of children with autism spectrum disorder. Marketing claims range from cautious ("may improve attention and social engagement") to specific ("reverses neuroinflammation"). Protocols typically involve 40-80 sessions over several months at $200-400 per session — a total cost commonly in the $8,000-$30,000 range.

What major pediatric institutions actually say

Texas Children's Hospital — One of the largest pediatric medical centers in the United States, with a dedicated autism services program. Their autism program page lists evidence-based interventions (applied behavior analysis, speech and occupational therapy, medications for co-occurring conditions). It does not mention hyperbaric oxygen therapy. As of mid-2026, a search of their patient-facing content for "hyperbaric" or "HBOT" returns no result describing it as part of their autism care offering.

Boston Children's Hospital — Comparable silence. The autism programs run by major pediatric centers in the US do not, in their published patient guidance, recommend HBOT for autism. They do recommend specific behavioral and medical interventions in detail.

Cleveland Clinic — Their patient-facing HBOT page lists the 14 FDA-approved indications. Autism is not among them. The page does not mention autism in any context — neither to endorse nor to caution against the off-label use.

Mayo Clinic — Similar. The Mayo Clinic patient guide on HBOT (publicly accessible) covers the FDA-approved uses in detail. It does not discuss autism, ADHD, anti-aging, or other off-label applications.

The Autism Science Foundation has explicitly weighed in

Unlike the silent institutions, the Association for Science in Autism Treatment — a nonprofit organization founded to evaluate autism interventions for evidence quality — has published a direct position. As of their most recent update, the position is:

"There is no quality empirical research that demonstrates that hyperbaric oxygen therapy is an effective treatment for autism."

The organization details the methodological problems with the small trials that have been conducted (mostly open-label, parent-rated outcomes, no control arms). It cautions families about the financial cost relative to the evidence base.

What does this pattern tell us?

When the major pediatric medical centers — which actively recommend evidence-based interventions in detail — choose to say nothing about a treatment marketed heavily to their patient population, that is itself a position.

The institutions could be wrong. They could be over-cautious. They could be missing a real effect that hasn't yet been demonstrated in trials of the quality they require. But the pattern is uniform across multiple respected pediatric institutions, and the trade association most directly focused on evaluating autism treatments has gone further than silence — they've actively flagged the gap in evidence.

For a parent weighing $20,000 in cash-pay HBOT, the absence of endorsement from Texas Children's or Boston Children's is information worth weighing.

HBOT for traumatic brain injury (TBI) — the VA situation

What's being marketed

HBOT for traumatic brain injury — especially for combat-related TBI and post-concussion syndrome in veterans — has been heavily promoted since the early 2010s. Private clinics market 40-80 session protocols at $200-400 per session, often targeting veterans and their families directly. Athlete endorsements (Aaron Rodgers post-Achilles, various NFL alumni) drive much of the consumer-facing visibility.

What the VA actually says

The Department of Veterans Affairs is the largest single healthcare provider for combat veterans in the United States. Their position on HBOT for TBI has been publicly maintained for over a decade.

The VA's official guidance does not currently cover HBOT for the treatment of traumatic brain injury as a standard benefit. The agency has reviewed the available evidence in multiple internal assessments. Their published reasoning, summarized, has been:

• The existing trials are mostly small and have produced mixed results
• The placebo-controlled trials that have been conducted have not consistently shown an effect distinguishable from sham (room-air at slightly elevated pressure)
• The standard of evidence required for VA coverage has not been met

This position has been the subject of sustained political pressure. H.R. 1336 (119th Congress) — introduced in 2025 — would require the VA to cover HBOT for TBI as a covered benefit. The bill's text characterizes HBOT for TBI as "well-proven," which is rhetorically stronger than the underlying RCT base supports. As of mid-2026, the bill remains in committee.

The clinical trials in progress

While the VA hasn't moved, research continues. NCT06665633 and several related trials are actively recruiting veterans for placebo-controlled studies of HBOT for blast-related TBI and PTSD. Trial results from earlier studies have been mixed — some showing improvements on neuropsychological testing, others showing no benefit over sham.

The honest read: the VA position is consistent with the evidence as it currently stands. That doesn't preclude future trial results changing the picture. It does mean that today, a veteran considering $20,000 of cash-pay HBOT for TBI is making a choice the agency dedicated to their care has explicitly declined to endorse, after looking at the same evidence the marketing claims rest on.

The interpretive challenge

The VA's resistance is sometimes framed by HBOT advocates as bureaucratic inertia or institutional capture. There may be some truth to that — large agencies are slow to change positions. But "slow to change" is not the same as "wrong." The VA's standard of evidence (multiple well-controlled RCTs replicating effect) is the standard the rest of medicine increasingly uses. Off-label HBOT for TBI has not yet met that standard. The advocacy push to change this through legislation rather than evidence is worth understanding for what it is.

HBOT for anti-aging — the elite-institution silence

What's being marketed

"Reverse biological aging" claims via 60-session HBOT protocols at 2.0 ATA, priced at $40,000-$50,000 cash. The marketing rests primarily on a single 2020 Tel Aviv University study (n=35, 3 months) measuring telomere length in blood cells. We wrote a separate critical analysis of those claims.

What major academic medical centers actually say

Mayo Clinic — No published patient guidance on HBOT for anti-aging or longevity. Their HBOT content covers FDA-approved indications.

Johns Hopkins — Same pattern. The university's healthcare system has not published patient-facing guidance endorsing or commenting on HBOT for anti-aging. Their longevity-related content (which is substantial — they have multiple longevity research programs) does not include HBOT among recommended interventions.

Stanford Medicine — Their longevity-research programs are publicly active. They publish on caloric restriction, exercise, specific medications. They do not publish endorsements of HBOT for biological age reversal.

UCLA Health — They operate one of the major academic hyperbaric medicine programs in the US. Their published indications page lists the standard 14 FDA-approved uses. Anti-aging is not on the list.

The pattern: institutions that actively publish on longevity research are not endorsing HBOT for that use. Institutions that operate hyperbaric medicine programs are not extending their patient guidance to anti-aging. Neither group has weighed in with explicit skepticism — they've simply not endorsed.

Why this pattern matters

Marketing claims often invoke specific institutions as a kind of borrowed authority — "the same hospitals using HBOT for wound care are increasingly using it for anti-aging." This framing collapses the distinction between approved use (where institutional reputation is at stake) and off-label use (where it isn't).

The institutions are NOT using HBOT for anti-aging as a matter of their published clinical practice. Individual physicians within those institutions may participate in off-label protocols elsewhere — that's a different question. But the institutional position, expressed through what they publish and offer to patients, is "we don't endorse this use."

HBOT for ADHD — even less institutional engagement

ADHD is one of the most-marketed off-label HBOT indications in wellness circles. The pattern of institutional engagement is:

• No major academic medical center has published patient-facing guidance endorsing HBOT for ADHD
• The American Academy of Pediatrics does not include HBOT among its recommended interventions for ADHD
• The American Academy of Child & Adolescent Psychiatry clinical guidelines for ADHD don't mention HBOT
• The FDA has not approved any HBOT indication for ADHD or related attention disorders

What does exist: clinic-marketing content claiming "proposed mechanisms" by which HBOT might affect neuroinflammation, dopaminergic signaling, etc. These mechanisms are biologically plausible in principle. But mechanism does not equal evidence of benefit in patients, and no major institution has published anything suggesting we've crossed that threshold.

HBOT for athletic recovery — institutional vs celebrity gap

The institutional silence vs marketing volume gap is largest in athletic recovery. High-profile endorsements (LeBron James, Aaron Rodgers, Joe Rogan) drive enormous search volume. The institutional layer offers almost nothing in response.

The American College of Sports Medicine has not published official guidance recommending HBOT for routine athletic recovery.

The NCAA does not have a published policy endorsing or restricting HBOT use among collegiate athletes.

The NFL allows individual teams to use HBOT chambers at their discretion (and several do, for injury rehabilitation). But there is no league-level evidence-based endorsement of HBOT as a routine recovery tool.

Peer-reviewed RCTs on HBOT for athletic performance enhancement: essentially zero of good quality. Most published work is on injury rehabilitation (a separate question with somewhat better evidence in specific contexts like soft-tissue injury or fracture healing) rather than performance enhancement.

The honest framing: celebrity use is not the same as evidence. A famous athlete using HBOT for documented injury rehabilitation does not validate the wellness center down the street marketing "performance enhancement protocols" to weekend warriors.

A note on consumer-protection institutions

While medical institutions stay mostly silent, some consumer-protection authorities have been more direct:

• The FDA has issued public warnings about HBOT marketing claims for unapproved indications, specifically calling out internet promotion of HBOT as a "universal treatment."
• The Federal Trade Commission has taken enforcement actions against HBOT clinics making specific deceptive claims (autism, cancer, COVID treatment in 2020).
• State attorneys general have occasionally pursued individual clinics making egregious claims.

The pattern: consumer-protection enforcement happens when claims become demonstrably false or when injuries occur. Medical-institutional engagement, by contrast, generally happens when evidence becomes sufficient for endorsement. The gap between these two activities is where most off-label HBOT marketing lives.

How to use this list when evaluating any HBOT claim

A practical checklist:

1. Is the claim about an FDA-approved indication? If yes, institutional engagement will be extensive and easy to find. If no, proceed to step 2.

2. Has a major academic medical center published patient-facing guidance endorsing this use? Search the institution's website directly. If yes, weight that as a meaningful signal. If no, that's information too.

3. Has the relevant specialty society (AAP for pediatrics, ACSM for sports medicine, etc.) published a position? If yes, read it carefully — these tend to be the most carefully-vetted documents.

4. Has the FDA, FTC, or state regulators issued any warnings or enforcement actions related to this use? Search the FDA's "Consumer Updates" and FTC press releases.

5. What does the trade association in this specific space say? (UHMS for hyperbaric medicine specifically.) The UHMS does maintain a list of conditions for which there is sufficient evidence to recommend HBOT — that list is the standard.

6. Is the institution offering the treatment financially compensated for it? Most academic medical centers don't market HBOT for off-label uses directly; private clinics do. The financial structure of the recommendation matters.

7. If multiple peer institutions have stayed silent for years on a heavily-marketed use, treat that as data. Silence is not always the absence of an opinion. Sometimes it's a quiet expression of one.

Sources

• Association for Science in Autism Treatment — HBOT Position
• FDA — Hyperbaric Oxygen Therapy: Get the Facts
• Cleveland Clinic — Hyperbaric Oxygen Therapy
• UCLA Health — Hyperbaric Medicine Indications
• Texas Children's Hospital — Autism Program
• Congress.gov — H.R. 1336 (119th Congress, 2025) Veterans HBOT Coverage
• ClinicalTrials.gov — NCT06665633 (HBOT for TBI trial)
• UHMS — Hyperbaric Oxygen Therapy Indications

Frequently asked questions

Does institutional silence prove an off-label HBOT use doesn't work? No. Silence is not the same as a negative finding. It means the institutions speaking in this space have not seen enough evidence to actively endorse the use — which is a different and weaker statement than "the use doesn't work." That said, when major peer institutions are uniformly silent for years on a heavily-marketed use, that pattern is meaningful.

Why don't institutions publish skeptical guidance on off-label HBOT? Several reasons. Publishing skepticism without strong negative trial data invites legal challenge. Institutions tend to publish what they recommend, not what they don't recommend. The opportunity cost of writing about every off-label claim is enormous. And in some cases, internal review may genuinely be ongoing.

Has any major institution publicly opposed off-label HBOT? The closest public statements come from the FDA (consumer warnings about unapproved-indication marketing) and the ASA (position on autism). Major hospitals tend not to publish "we don't recommend this" statements; they publish "we recommend this" statements.

Should I dismiss off-label HBOT entirely based on this institutional pattern? That's a personal decision involving your specific medical situation, your tolerance for risk and cost, and your evaluation of the existing evidence. The point of documenting institutional silence is not to dismiss off-label uses but to make sure the decision is made with full information. Many people invest tens of thousands of dollars in protocols without realizing the institutions they trust have chosen not to endorse them.

Is this list complete? No. The pattern of institutional silence is broader than what's documented here. We've focused on the most heavily-marketed off-label uses (autism, TBI, anti-aging, ADHD, athletic recovery) and the most prominent institutions in each space. The general pattern — heavy private-clinic marketing, near-zero institutional engagement — repeats across many other claimed HBOT indications.

Medical disclaimer: This article documents institutional positions and silences as observable from public sources. It is not medical advice. Decisions about any HBOT treatment, including off-label uses, should be made in consultation with a qualified physician. The institutions cited here may update or change their positions; please check current sources before making decisions.

— The HBOT Finder Team